Adicet Price To Sales Ratio vs Ev To Operating Cash Flow Analysis

ACET Stock

USD 0.90 0.01 1.10%

Adicet Bio financial indicator trend analysis is way more than just evaluating Adicet Bio prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adicet Bio is a good investment. Please check the relationship between Adicet Bio Price To Sales Ratio and its Ev To Operating Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adicet Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Adicet Stock please use our How to Invest in Adicet Bio guide.

Price To Sales Ratio vs Ev To Operating Cash Flow

Price To Sales Ratio vs Ev To Operating Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adicet Bio Price To Sales Ratio account and Ev To Operating Cash Flow. At this time, the significance of the direction appears to have pay attention.

The correlation between Adicet Bio's Price To Sales Ratio and Ev To Operating Cash Flow is -0.78. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Ev To Operating Cash Flow in the same time period over historical financial statements of Adicet Bio, assuming nothing else is changed. The correlation between historical values of Adicet Bio's Price To Sales Ratio and Ev To Operating Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Adicet Bio are associated (or correlated) with its Ev To Operating Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Operating Cash Flow has no effect on the direction of Price To Sales Ratio i.e., Adicet Bio's Price To Sales Ratio and Ev To Operating Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.78

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Adicet Bio stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Adicet Bio sales, a figure that is much harder to manipulate than other Adicet Bio multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Operating Cash Flow

A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.

Most indicators from Adicet Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adicet Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adicet Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Adicet Stock please use our How to Invest in Adicet Bio guide.At this time, Adicet Bio's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is expected to grow at the current pace this year, despite the fact that Enterprise Value is likely to grow to (54.6 M).

	2021	2022	2023	2024 (projected)
Interest Expense	176K	80K	25K	23.8K
Depreciation And Amortization	4.1M	5.0M	6.1M	5.2M

Interest Expense Depreciation And Amortization

Adicet Bio fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Good Will	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Net Receivables	Non Currrent Assets Other
Total Assets		-0.13	0.87	0.81	0.41	0.1	-0.47	-0.16	0.49	0.72	0.14	0.93	-0.01	-0.09	0.19	-0.47	-0.27	0.39	0.13	0.11	0.76	0.96	-0.03	0.69	0.29	0.43
Short Long Term Debt Total	-0.13		-0.09	0.02	0.12	-0.46	-0.31	0.8	0.27	0.0	-0.26	0.01	-0.33	0.96	-0.1	-0.13	0.84	0.65	-0.15	-0.42	0.11	-0.22	0.94	0.0	0.82	-0.88
Other Current Liab	0.87	-0.09		0.96	0.69	-0.17	-0.51	0.13	0.65	0.89	-0.3	0.92	-0.45	-0.08	-0.06	-0.35	-0.25	0.52	0.22	-0.19	0.89	0.75	0.02	0.87	0.37	0.44
Total Current Liabilities	0.81	0.02	0.96		0.69	-0.34	-0.6	0.27	0.79	0.97	-0.39	0.86	-0.55	0.04	-0.15	-0.38	-0.15	0.68	0.33	-0.36	0.9	0.7	0.14	0.96	0.51	0.32
Total Stockholder Equity	0.41	0.12	0.69	0.69		-0.38	-0.51	0.44	0.5	0.69	-0.64	0.53	-0.72	0.11	-0.01	-0.12	-0.1	0.59	0.25	-0.25	0.59	0.29	0.24	0.7	0.5	0.09
Property Plant And Equipment Net	0.1	-0.46	-0.17	-0.34	-0.38		0.11	-0.82	-0.78	-0.43	0.79	-0.03	0.72	-0.44	0.52	-0.4	-0.35	-0.59	-0.28	0.92	-0.38	0.19	-0.44	-0.45	-0.56	0.27
Current Deferred Revenue	-0.47	-0.31	-0.51	-0.6	-0.51	0.11		-0.24	-0.41	-0.64	0.08	-0.43	0.31	-0.37	-0.29	0.63	0.06	-0.77	-0.26	0.01	-0.37	-0.47	-0.49	-0.64	-0.63	0.24
Net Debt	-0.16	0.8	0.13	0.27	0.44	-0.82	-0.24		0.59	0.3	-0.77	0.08	-0.78	0.75	-0.42	0.14	0.67	0.72	0.02	-0.8	0.35	-0.31	0.77	0.31	0.78	-0.6
Retained Earnings	0.49	0.27	0.65	0.79	0.5	-0.78	-0.41	0.59		0.84	-0.59	0.57	-0.67	0.3	-0.45	-0.06	0.17	0.77	0.37	-0.78	0.75	0.38	0.35	0.85	0.65	0.03
Accounts Payable	0.72	0.0	0.89	0.97	0.69	-0.43	-0.64	0.3	0.84		-0.44	0.75	-0.6	0.03	-0.18	-0.35	-0.18	0.71	0.48	-0.43	0.83	0.63	0.14	0.99	0.51	0.29
Cash	0.14	-0.26	-0.3	-0.39	-0.64	0.79	0.08	-0.77	-0.59	-0.44		-0.11	0.94	-0.2	0.58	-0.35	-0.2	-0.46	-0.16	0.78	-0.41	0.31	-0.26	-0.46	-0.39	0.07
Non Current Assets Total	0.93	0.01	0.92	0.86	0.53	-0.03	-0.43	0.08	0.57	0.75	-0.11		-0.27	0.03	-0.02	-0.43	-0.07	0.48	-0.02	-0.09	0.86	0.8	0.1	0.73	0.39	0.35
Cash And Short Term Investments	-0.01	-0.33	-0.45	-0.55	-0.72	0.72	0.31	-0.78	-0.67	-0.6	0.94	-0.27		-0.28	0.58	-0.02	-0.27	-0.64	-0.25	0.76	-0.53	0.17	-0.37	-0.63	-0.54	0.11
Good Will	-0.09	0.96	-0.08	0.04	0.11	-0.44	-0.37	0.75	0.3	0.03	-0.2	0.03	-0.28		-0.04	-0.14	0.83	0.7	-0.17	-0.37	0.03	-0.16	0.99	0.03	0.85	-0.91
Common Stock Shares Outstanding	0.19	-0.1	-0.06	-0.15	-0.01	0.52	-0.29	-0.42	-0.45	-0.18	0.58	-0.02	0.58	-0.04		-0.12	-0.39	-0.13	-0.16	0.74	-0.26	0.33	-0.03	-0.2	-0.09	-0.05
Short Term Investments	-0.47	-0.13	-0.35	-0.38	-0.12	-0.4	0.63	0.14	-0.06	-0.35	-0.35	-0.43	-0.02	-0.14	-0.12		-0.11	-0.39	-0.21	-0.26	-0.24	-0.46	-0.23	-0.35	-0.32	0.08
Non Current Liabilities Total	-0.27	0.84	-0.25	-0.15	-0.1	-0.35	0.06	0.67	0.17	-0.18	-0.2	-0.07	-0.27	0.83	-0.39	-0.11		0.41	-0.17	-0.45	-0.04	-0.38	0.78	-0.17	0.62	-0.78
Inventory	0.39	0.65	0.52	0.68	0.59	-0.59	-0.77	0.72	0.77	0.71	-0.46	0.48	-0.64	0.7	-0.13	-0.39	0.41		0.27	-0.54	0.55	0.28	0.78	0.72	0.94	-0.45
Other Current Assets	0.13	-0.15	0.22	0.33	0.25	-0.28	-0.26	0.02	0.37	0.48	-0.16	-0.02	-0.25	-0.17	-0.16	-0.21	-0.17	0.27		-0.23	0.17	0.22	-0.11	0.46	0.16	0.16
Other Stockholder Equity	0.11	-0.42	-0.19	-0.36	-0.25	0.92	0.01	-0.8	-0.78	-0.43	0.78	-0.09	0.76	-0.37	0.74	-0.26	-0.45	-0.54	-0.23		-0.45	0.24	-0.38	-0.45	-0.49	0.19
Total Liab	0.76	0.11	0.89	0.9	0.59	-0.38	-0.37	0.35	0.75	0.83	-0.41	0.86	-0.53	0.03	-0.26	-0.24	-0.04	0.55	0.17	-0.45		0.61	0.1	0.82	0.43	0.35
Total Current Assets	0.96	-0.22	0.75	0.7	0.29	0.19	-0.47	-0.31	0.38	0.63	0.31	0.8	0.17	-0.16	0.33	-0.46	-0.38	0.28	0.22	0.24	0.61		-0.12	0.61	0.19	0.44
Intangible Assets	-0.03	0.94	0.02	0.14	0.24	-0.44	-0.49	0.77	0.35	0.14	-0.26	0.1	-0.37	0.99	-0.03	-0.23	0.78	0.78	-0.11	-0.38	0.1	-0.12		0.14	0.9	-0.88
Common Stock	0.69	0.0	0.87	0.96	0.7	-0.45	-0.64	0.31	0.85	0.99	-0.46	0.73	-0.63	0.03	-0.2	-0.35	-0.17	0.72	0.46	-0.45	0.82	0.61	0.14		0.51	0.29
Net Receivables	0.29	0.82	0.37	0.51	0.5	-0.56	-0.63	0.78	0.65	0.51	-0.39	0.39	-0.54	0.85	-0.09	-0.32	0.62	0.94	0.16	-0.49	0.43	0.19	0.9	0.51		-0.63
Non Currrent Assets Other	0.43	-0.88	0.44	0.32	0.09	0.27	0.24	-0.6	0.03	0.29	0.07	0.35	0.11	-0.91	-0.05	0.08	-0.78	-0.45	0.16	0.19	0.35	0.44	-0.88	0.29	-0.63

Click cells to compare fundamentals

Adicet Bio Account Relationship Matchups

Adicet Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	81.6M	153.8M	338.9M	330.7M	207.3M	215.3M
Short Long Term Debt Total	114.1M	21.6M	20.9M	21.0M	20.9M	19.9M
Other Current Liab	2.8M	4.5M	5.1M	10.3M	10.2M	18.3M
Total Current Liabilities	14.9M	14.0M	16.3M	19.7M	19.3M	18.3M
Total Stockholder Equity	(60.4M)	(106.3M)	(168.3M)	(238.1M)	170.2M	178.7M
Property Plant And Equipment Net	2.1M	25.9M	35.0M	49.0M	44.2M	46.4M
Net Debt	103.5M	(62.7M)	(256.6M)	(236.6M)	(138.8M)	(131.8M)
Retained Earnings	(69.6M)	(106.3M)	(168.3M)	(238.1M)	(380.8M)	(361.7M)
Accounts Payable	1.1M	1.6M	3.3M	4.4M	2.6M	2.5M
Cash	10.6M	84.3M	277.5M	257.7M	159.7M	83.6M
Non Current Assets Total	17.4M	59.2M	56.5M	69.7M	45.0M	58.4M
Cash And Short Term Investments	62.4M	94.6M	277.5M	257.7M	159.7M	95.6M
Common Stock Shares Outstanding	15.0M	7.3M	31.0M	41.1M	43.0M	28.0M
Liabilities And Stockholders Equity	81.6M	153.8M	(132.5M)	(199.8M)	207.3M	165.2M
Non Current Liabilities Total	127.1M	246.2M	19.5M	18.6M	17.8M	16.9M
Other Current Assets	179K	5.6M	4.7M	2.9M	2.6M	2.4M
Other Stockholder Equity	(106.7M)	62.3M	471.4M	530.4M	550.9M	578.5M
Total Liab	142.0M	44.0M	35.8M	38.4M	37.1M	35.3M
Total Current Assets	64.2M	94.6M	282.4M	261.0M	162.3M	156.9M
Accumulated Other Comprehensive Income	(5.1M)	(41K)	23K	24K	(338.9M)	0.0
Common Stock	1K	3K	4K	2K	3.6K	3.4K
Non Currrent Assets Other	4.7M	12.1M	2.0M	1.2M	822K	863.1K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Adicet Stock Analysis

When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC